Drug Sales
The latest news about Drug Sales: headlines, AI summaries and the full story from every source.
- Madrigal Pharmaceuticals Achieves First Profitable Quarter Driven by Rezdiffra Sales Growth
- Regeneron Reports 36% Year-Over-Year Revenue Growth in Q3 2026
- Regeneron Reports Strong Q3 2026 Results Driven by Sanofi Collaboration and Libtayo Growth
- AbbVie Successfully Transitions Revenue from Humira to New Immunology and Neuroscience Growth Engines
- Kiniksa Pharmaceuticals Raises 2026 Revenue Guidance Following Strong ARCALYST Sales
- Regeneron's Future May Depend on Dupixent Amid Eylea Sales Decline
- Bristol Myers Squibb Raises Full-Year Forecast on Strong Performance of Eliquis and Newer Drugs
- Novartis Reports Better-Than-Expected Q2 Sales Amid Upcoming Patent Challenges
- Novartis Reports Stronger Q2 Profits Amid Transition to New Medicines
- Regeneron's FDA Approved Gene Therapy for Hearing Loss Amid Mixed Financial Results
- Axsome Therapeutics Stock Rises Over 20% in April Due to FDA Approval for New Indication
- Eli Lilly Reports Strong Q1 2026 Earnings, Raised Guidance Due to Mounjaro and Zepbound Sales
- Bristol Myers Squibb Exceeds First-Quarter Profit Estimates Due to Strong Sales of Eliquis and Cancer Drugs
- AbbVie Exceeds First-Quarter 2026 Earnings and Raises Full-Year Forecast
- AbbVie Raises 2026 Earnings Guidance, Boosting Stock
- AbbVie Exceeds Quarterly Revenue and Profit Expectations as Newer Immunology Drugs Offset Humira Decline
- Johnson & Johnson Reports Q1 2026 Earnings, Beats Estimates but Faces Patent Expiry Concerns